10th Neurodegenerative Drug Development Summit
Evvnt Promotion / evvnt
28.03.2022 - 30.03.2022 Boston Park Plaza, 50 Park Plaza, 02116 Boston, USA
Time: 8:00 AM - 3:30 PM
Temas de la conferencia
With Biogen’s Aducanumab approval dramatically overhauling the regulatory landscape for neurodegenerative disease, the beta amyloid revival is in full swing with investment pouring in across multiple neurodegenerative diseases. With this, biopharma across the globe are racing to harness the exhilarating momentum of the past year and turbocharge their neurodegenerative disease drug development in 2022 and beyond.
With Biogen’s Aducanumab approval dramatically overhauling the regulatory landscape for neurodegenerative disease, the beta amyloid revival is in full swing with investment pouring in across multiple neurodegenerative diseases. With this, biopharma across the globe are racing to harness the exhilarating momentum of the past year and turbocharge their neurodegenerative disease drug development in 2022 and beyond.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Información e inscripción:
https://go.evvnt.com/961759-2?pid=4832
Ms. Stephanie Nketia
Investigación clínica, Medicina General
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
